Overview

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Status:
Active, not recruiting

Trial end date:
2022-04-02

Target enrollment:

Participant gender:

Summary

This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.

Phase:

Phase 3

Details

Lead Sponsor:

Medical University of Graz

Collaborators:

Barmherzige Brüder Eisenstadt
Hospital Rudolfstiftung
Johannes Kepler University of Linz
Kardinal Schwarzenberg Klinikum Schwarzach St. Veit
Kepler University Hospital
Klinikum Klagenfurt am Wörthersee
Krankenhaus der Barmherzigen Brüder Linz
Landesklinikum Sankt Polten
Landeskrankenhaus Feldkirch
Landeskrankenhaus II Graz West
Medical University of Vienna
Paracelsus Medical University
United Arab Emirates University

Treatments:

Empagliflozin